Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.
Kathryn E. Beckermann, MD, PhD
Advertisement
Kathryn E. Beckermann, MD, PhD, is director of Genitourinary Cancer Research at Tennessee Oncology
Articles by Kathryn E. Beckermann, MD, PhD
Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.
Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).
Kathryn E. Beckermann, MD, PhD, discusses treatment selection in metastatic renal cell carcinoma.
The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
5